MAIL STOP AMENDMENT

AMENDMENTS TO THE CLAIMS

(Currently Amended) A method of the treatment of a patient in need of such

treatment comprising administering to the patient for inhalation a nebulized unit dose of 4.0 ml

or less of a nebulized aerosol formulation an aqueous solution comprising from about 60 to about

200 mg/ml of an aminoglycoside antibiotic tobramycin in for a duration of nebulization less than

about 10 minutes, using an inhalation device having a rate of aerosol output of not less than

about 4 Tl/sec.

1.

2. (Currently Amended) A method of Claim 1 wherein the unit dose comprises less

than about 3.75 ml of the nebulized aerosol formulation aqueous solution.

3. (Currently Amended) A method of Claim 1 wherein the <u>unit</u> dose comprises 3.5

ml or less of the nebulized aerosol formulation aqueous solution.

4. (Currently Amended) A method of Claim 1 wherein the aerosol formulation

aqueous solution comprises from about 80 to about 180 mg/ml of the aminoglycoside antibiotic

tobramycin.

5. (Currently Amended) A method of Claim 1 wherein the aerosol formulation

aqueous solution comprises from about 90 to about 150 mg/ml of the aminoglycoside antibiotic

tobramycin.

6-7. (Canceled)

8. (Currently Amended) A method of Claim 7-1 wherein the <u>unit</u> dose comprises

3.5 ml or less of a nebulized aerosol formulation an aqueous solution comprising from about 80

to about 180 mg/ml of tobramycin.

9-17. (Canceled)

18. (New) A method of Claim 1 wherein the inhalation device has a rate of aerosol

-3-

output of not less than about 5 Tl/sec.

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC 1420 Fifth Avenue

Suite 2800 Seattle, Washington 98101

206.682.8100

19. (New) A method of Claim 1 wherein the inhalation device has a rate of aerosol output of not less than about 8 Tl/sec.

20. (New) A method of Claim 1 wherein the inhalation device has an emitted dose

efficiency of at least about 68 percent.

21. (New) A method of Claim 1 wherein the inhalation device has an emitted dose

efficiency of at least about 75 percent.

22. (New) A method of Claim 1 wherein the inhalation device has an emitted dose

efficiency of at least about 80 percent.

23. (New) A method of Claim 1 wherein the inhalation device has an emitted dose

efficiency of at least about 85 percent.

24. (New) A method of Claim 1 wherein the duration of nebulization is less than

about 8 minutes.

25. (New) A method of Claim 1 wherein the duration of nebulization is less than

about 6 minutes.

26. (New) A method of Claim 1 wherein the inhalation device is breath actuated.

27. (New) A method of Claim 1 wherein at least 20 mg of tobramycin is

administered to the patient.

28. (New) A method of the treatment of a patient in need of such treatment

comprising administering to the patient for inhalation a nebulized unit dose of 3.5 ml or less of

an aqueous solution comprising from about 90 to about 150 mg/ml of tobramycin for a duration

of nebulization less than about 6 minutes, using an inhalation device having a rate of aerosol

output of not less than about 4 Tl/sec.

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESS'LLC 1420 Fifth Avenue

Suite 2800 Seattle, Washington 98101 206.682.8100

-4-